DOCSLIB.ORG

2020 Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Annual Report Advanced Oncotherapy plc Annual Report 2020 Democratising Proton Therapy Advancing cancer treatment with innovative, cost effective technology Advanced Oncotherapy plc. Annual Report 2017 Advanced Oncotherapy plc Annual Report 2018 Advancing cancer treatment with innovative, cost effective technology Advancing cancer treatment with innovative, cost effective technology Advanced Oncotherapy plc Advanced Oncotherapy plc Annual Report Annual Report 2019 2020 Democratising Proton Therapy Advancing cancer treatment with innovative, cost effective technology Democratising Proton Therapy Advancing cancer treatment with innovative, cost effective technology This report is available on our website www.avoplc.com/en-gb/Investors/Company-Documents ADVANCED ONCOTHERAPY PLC 1 TO OUR SHAREHOLDERS STRATEGIC REPORT OUR PURPOSE We are driven by our purpose: democratising proton therapy. Just as the mobile revolution democratised communication among people, healthcare must be democratised. At Advanced Oncotherapy, we believe access to healthcare is a fundamental human right. Yet, the provision of healthcare is still not universal and many people cannot afford quality health services. Proton therapy is one of the many segments in healthcare where a different global approach that is truly democratic must emerge. Fundamentally, we believe in a new model that will change the way we treat cancer, and the relationship between patients and physicians as we know it. TO OUR SHAREHOLDERS FINANCIAL REPORT Consolidated Statement of Profit or Loss and STRATEGIC REPORT Other Comprehensive Income 108 Introduction to Advanced Oncotherapy 8 Consolidated Statement of Financial Position 109 Why our Commitment to Patients? 24 Consolidated Statement of Changes in Equity 110 What We Do 30 Consolidated Statement of Cash Flows 111 How We Do It 58 Notes Forming Part of the Financial Statements 113 Notes to the Accounts – Group 114 GOVERNANCE REPORT Company Statement of Financial Position 138 Advanced Oncotherapy Team 76 Company Statement of Changes in Equity 139 Corporate Governance Report 82 Notes to the Accounts – Company 140 Statement of Directors' Responsibilities 88 Audit Committee Report 90 OTHER INFORMATION Remuneration Committee Report 92 Notice of Annual General Meeting 148 Section 172 Statement 96 Explanatory Notes to the Notice of Annual Group Directors' Report 98 General Meeting 150 Independent Auditor’s Report 102 Company Information 152 ONLINE You can find more information about Advanced Oncotherapy at www.avoplc.com 2 ANNUAL REPORT 2020 GOVERNANCE REPORT FINANCIAL REPORT OTHER INFORMATION We know accessibility and affordability are hindering the widespread use of proton therapy. Innovation in healthcare breaks down these walls of cost, time and location. With our technology originated at the world- renowned place of excellence and science – CERN – we work every day to make proton therapy a reality for every patient. Our LIGHT technology possesses the power to remove the obstacles which are associated with legacy systems and which prevent access to proton therapy for all. ADVANCED ONCOTHERAPY PLC 3 TO OUR SHAREHOLDERS STRATEGIC REPORT TO OUR SHAREHOLDERS Dear shareholders, platforms and minimising the number of hospital patient visits through more efficient and targeted radiation therapy It is my great pleasure to introduce another annual report and systems. These new solutions facilitate access to innovation accounts at such a pivotal time in Advanced Oncotherapy’s of cancer centres and support more partnerships to accelerate development. the convergence of radiation with targeted drugs. These are a few important changes we foresee and which we believe 2020 will certainly be remembered all over the world for the will continue well beyond the short- to mid-term of the active Covid-19 pandemic, an unprecedented health crisis of epic proportions bearing profound social, economic and financial pandemic. consequences. My first and foremost thoughts are for all of those • The Covid-19 pandemic has taken a terrible toll around the who lost their dear ones over the past year. I also world – but some sectors have been more want to express my utmost gratitude to all our affected than others. People with underlying employees and partners who have shown conditions, including cancer, or those remarkable dedication, agility and resilience living in countries with under-developed during these unprecedented circumstances. healthcare infrastructure have been hit disproportionately hard by the virus. As Albert Einstein suggested, out of This makes our purpose centred crises can emerge new and incredible around defeating cancer through opportunities, particularly if traditional the democratisation of proton approaches and paradigms are therapy more meaningful than questioned and challenged. This ever. We want to play our part Covid-19 pandemic is no exception; it underscores three major opportunities and have an impact in broadening for Advanced Oncotherapy: access to cancer therapy by making • The Covid-19 pandemic has been a proton therapy more accessible wake-up call for governments to do more and affordable. All the decisions we to tackle cancer. Cancer is a pandemic have taken were not always the easiest in itself and time is exceedingly precious. ones, but they were the right ones to Every minute during 2020, nine people were serve our purpose and I am convinced that diagnosed with cancer in Western Europe1. many patients around the world and all our A one-month delay in treating cancer results in a 6 to 13% stakeholders will soon reap the rewards of our strategy. higher risk of dying2. Sadly, 50% of governments had their In the face of these challenges, we continued to make progress cancer services partially or completely disrupted as a result of on our strategy. This is a testament to the leadership of Nicolas the Covid-19 pandemic3 and it is estimated that some 50,000 4 and his management team who have navigated the Company people in the UK are probably missing a cancer diagnosis . through the year and ensured people across our Company Yet, the stark impact of the pandemic on cancer care has remained focused on our purpose and project. Ensuring our made everyone realise the actual human cost of neglecting LIGHT system can deliver a proton beam for all radio-sensitive non-communicable diseases like cancer. With the number tumours remains our number one priority for 2021. of new cancer cases currently expected to rise by more than 45% over the next twenty years5, more actions must be taken The success of our strategy and execution plan relies on well- to bend the curve and raise further awareness at all levels. We proven design and industrial processes. It is also predicated on have already seen governments, payers and other healthcare four important strategic pillars: stakeholders seeking new ways to accelerate the fight against • differentiated, asset-light and patient-centric business model; cancer and deploy new initiatives. Advanced Oncotherapy • commitment to do business responsibly and sustainably; has a key role to play in this broad eco-system. • continued innovation with clear metrics to prioritise • The Covid-19 pandemic is reshaping oncology practice and initiatives and assess their expected return; and delivery of cancer care broadly, shifting care onto virtual • unique culture embedded in our governance framework. “I am confident that the business model we are building around the superiority of LIGHT and centred around customers' needs is a long-term sustainable growth model that will prove rewarding for Advanced Oncotherapy's shareholders” 1 Source: WHO 2 Source: The British Medical Journal 3 Dr. André Ilbawi, from WHO 4 Source: Macmillan Cancer Support 5 Source: WHO 6 This is approximately ten times faster than cyclotrons 7 Up to 10 times smaller versus cyclotrons 4 ANNUAL REPORT 2020 GOVERNANCE REPORT FINANCIAL REPORT OTHER INFORMATION DIFFERENTIATED, ASSET-LIGHT AND PATIENT-CENTRIC In summary, I am confident that the business model we are building BUSINESS MODEL around the superiority of LIGHT and centred around customers’ The commercial launch of LIGHT represents a shift away from needs is a long-term sustainable growth model that will prove competition and into a space where, as a technology disrupter, rewarding for Advanced Oncotherapy’s shareholders. we can provide long-term attractive return opportunities for our customers. COMMITMENT TO DO BUSINESS RESPONSIBLY AND SUSTAINABLY WITH A CLEAR SOCIAL PURPOSE LIGHT has been designed to treat at an affordable cost a large Many years ago, CERN designed LIGHT with the view of doing spectrum of tumours. Its potential goes well beyond the hard- the right thing for patients, society and our planet: to-treat tumours such as head and neck tumours. Its ability • it can be installed in a contiguous and densely populated to deliver radiation pulse-by-pulse 200 times per second6 environment, allowing patients to be treated at proximity to 7 combined with its significantly narrower proton beam make it their families; perfectly suited to sculpt radiation doses based on the irregular • it can be easily installed directly into existing clinical facilities; shape of the tumour, taking into account potential tumour motion • it can be transported in standard containers and trucks; it does as a result of breathing and heart movements. not require expensive cranes or load handling devices; and As we seek to deliver our mission of democratising proton • as a result of being able to be operated with an efficiency
Load more

Recommended publications
  • Proton Stereotactic Body Radiation Therapy for Liver Metastases— Results of 5-Year Experience for 81 Hepatic Lesions
    1760 Original Article Proton stereotactic body radiation therapy for liver metastases— results of 5-year experience for 81 hepatic lesions Alex R. Coffman1, Daniel C. Sufficool2, Joseph I. Kang1, Chung-Tsen Hsueh3, Sasha Swenson4, Patrick Q. McGee4, Gayathri Nagaraj3, Baldev Patyal1, Mark E. Reeves5, Jerry D. Slater1, Gary Y. Yang1 1Department of Radiation Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA; 2Department of Radiation Oncology, Kettering Health Network, Kettering, OH, USA; 3Department of Medical Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA; 4Loma Linda University School of Medicine, Loma Linda, CA, USA; 5Department of Surgical Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA Contributions: (I) Conception and design: GY Yang; (II) Administrative support: B Patyal, JD Slater, GY Yang; (III) Provision of study materials or patients: CT Hsueh, G Nagaraj, ME Reeves; (IV) Collection and assembly of data: AR Coffman, GY Yang; (V) Data analysis and interpretation: AR Coffman, GY Yang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Alex R. Coffman, MD. Department of Radiation Oncology, Loma Linda University Medical Center, 11234 Anderson Street, Suite B121, Loma Linda, CA 92354, USA. Email: acoffman@llu.edu. Background: To report on our institutional experience using Proton stereotactic body radiation therapy (SBRT) for patients with liver metastases. Methods: All patients with liver metastases treated with Proton SBRT between September 2012 and December 2017 were retrospectively analyzed. Local control (LC) and overall survival (OS) were estimated using the Kaplan-Meier method calculated from the time of completion of Proton SBRT. LC was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1).
    [Show full text]
  • An Analysis of Vertebral Body Growth After Proton Beam Therapy for Pediatric Cancer
    cancers Article An Analysis of Vertebral Body Growth after Proton Beam Therapy for Pediatric Cancer Keiichiro Baba 1, Masashi Mizumoto 1,* , Yoshiko Oshiro 1,2, Shosei Shimizu 1 , Masatoshi Nakamura 1, Yuichi Hiroshima 1 , Takashi Iizumi 1, Takashi Saito 1, Haruko Numajiri 1, Kei Nakai 1 , Hitoshi Ishikawa 1,3, Toshiyuki Okumura 1, Kazushi Maruo 4 and Hideyuki Sakurai 1 1 Proton Medical Research Center, Department of Radiation Oncology, University of Tsukuba Hospital, Tsukuba, Ibaraki 305-8576, Japan; baba@pmrc.tsukuba.ac.jp (K.B.); ooyoshiko@pmrc.tsukuba.ac.jp (Y.O.); shimizu@pmrc.tsukuba.ac.jp (S.S.); nakamura@pmrc.tsukuba.ac.jp (M.N.); hiroshima@pmrc.tsukuba.ac.jp (Y.H.); iizumi@pmrc.tsukuba.ac.jp (T.I.); saitoh@pmrc.tsukuba.ac.jp (T.S.); haruko@pmrc.tsukuba.ac.jp (H.N.); knakai@pmrc.tsukuba.ac.jp (K.N.); ishikawa.hitoshi@qst.go.jp (H.I.); okumura@pmrc.tsukuba.ac.jp (T.O.); hsakurai@pmrc.tsukuba.ac.jp (H.S.) 2 Department of Radiation Oncology, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki 305-8558, Japan 3 National Institutes for Quantum and Radiological Science and Technology, QST Hospital, Chiba 263-8555, Japan 4 Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan; maruo@md.tsukuba.ac.jp * Correspondence: mizumoto@pmrc.tsukuba.ac.jp; Tel.: +81-29-853-7100; Fax: +81-29-853-7102 Simple Summary: Radiotherapy has a key role in treatment of pediatric cancer and has greatly improved survival in recent years. However, vertebrae are often included in the irradiated area, and this may affect growth after treatment.
    [Show full text]
  • Particle Accelerators and Detectors for Medical Diagnostics and Therapy Arxiv:1601.06820V1 [Physics.Med-Ph] 25 Jan 2016
    Particle Accelerators and Detectors for medical Diagnostics and Therapy Habilitationsschrift zur Erlangung der Venia docendi an der Philosophisch-naturwissenschaftlichen Fakult¨at der Universit¨atBern arXiv:1601.06820v1 [physics.med-ph] 25 Jan 2016 vorgelegt von Dr. Saverio Braccini Laboratorium f¨urHochenenergiephysik L'aspetto pi`uentusiasmante della scienza `eche essa incoraggia l'uomo a insistere nei suoi sogni. Guglielmo Marconi Preface This Habilitation is based on selected publications, which represent my major sci- entific contributions as an experimental physicist to the field of particle accelerators and detectors applied to medical diagnostics and therapy. They are reprinted in Part II of this work to be considered for the Habilitation and they cover original achievements and relevant aspects for the present and future of medical applications of particle physics. The text reported in Part I is aimed at putting my scientific work into its con- text and perspective, to comment on recent developments and, in particular, on my contributions to the advances in accelerators and detectors for cancer hadrontherapy and for the production of radioisotopes. Dr. Saverio Braccini Bern, 25.4.2013 i ii Contents Introduction 1 I 5 1 Particle Accelerators and Detectors applied to Medicine 7 2 Particle Accelerators for medical Diagnostics and Therapy 23 2.1 Linacs and Cyclinacs for Hadrontherapy . 23 2.2 The new Bern Cyclotron Laboratory and its Research Beam Line . 39 3 Particle Detectors for medical Applications of Ion Beams 49 3.1 Segmented Ionization Chambers for Beam Monitoring in Hadrontherapy 49 3.2 Proton Radiography with nuclear Emulsion Films . 62 3.3 A Beam Monitor Detector based on doped Silica Fibres .
    [Show full text]
  • Proton Therapy ACKNOWLEDGEMENTS
    AMERICAN BRAIN TUMOR ASSOCIATION Proton Therapy ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely to brain tumor research. For over 40 years, the Chicago-based ABTA has been providing comprehensive resources that support the complex needs of brain tumor patients and caregivers, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnosis, treatment and care. To learn more about the ABTA, visit www.abta.org. We gratefully acknowledge Anita Mahajan, Director of International Development, MD Anderson Proton Therapy Center, director, Pediatric Radiation Oncology, co-section head of Pediatric and CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center; Kevin S. Oh, MD, Department of Radiation Oncology, Massachusetts General Hospital; and Sridhar Nimmagadda, PhD, assistant professor of Radiology, Medicine and Oncology, Johns Hopkins University, for their review of this edition of this publication. This publication is not intended as a substitute for professional medical advice and does not provide advice on treatments or conditions for individual patients. All health and treatment decisions must be made in consultation with your physician(s), utilizing your specific medical information. Inclusion in this publication is not a recommendation of any product, treatment, physician or hospital. COPYRIGHT © 2015 ABTA REPRODUCTION WITHOUT PRIOR WRITTEN PERMISSION IS PROHIBITED AMERICAN BRAIN TUMOR ASSOCIATION Proton Therapy INTRODUCTION Brain tumors are highly variable in their treatment and prognosis. Many are benign and treated conservatively, while others are malignant and require aggressive combinations of surgery, radiation and chemotherapy.
    [Show full text]
  • PIONEERING THERAPY for LIFE Table of Contents
    PIONEERING THERAPY FOR LIFE Table of contents Key figures 20151 IBA at a glance 2 IBA is 30 years old 4 Proton therapy 6 Dosimetry 20 RadioPharma Solutions 24 Industrial 26 Human resources 28 Corporate social responsibility 30 Governance 36 Economical review 39 IFRS consolidated financial statements for the year ended December 31, 2015 73 IBA SA Annual financial statements148 General information 152 Stock market and shareholders 157 Key figures 2015 REBIT (3) / SALES & SERVICES TRENDS 12% 12 IBA is a high-technology medical 10.9% company which concentrates 10% 10 its activities on proton therapy, radiopharmacy, particle accelerators 8 8% for industry, and dosimetry. 6% IBA is the worldwide leader in 6 the proton therapy market. 4 4% Listed on the NYSE Euronext Brussels. 2 2% 1 200 employees worldwide. 0% IBA operates in two areas: “Proton 0 Therapy and Other Accelerators ” and 2010 2011 2012 2013 2014 2015 “Dosimetry”. Key figures 2015 + 22.6% 332 2015 revenue increase EUR million Backlog in Proton Therapy & Other Accelerators OPERATING RESULTS 2014 2015 Change CAGR (1) (EUR 000) (EUR 000) (EUR 000) (%) 2014/2015 Sales and services 220 577 270 357 49 780 22.60% Gross margin 96 096 113 655 18.30% REBITDA (2) 28 321 33 710 5 389 19.00% REBITDA/Sales and services 12.80% 12.50% REBIT (3) 22 932 29 553 6 621 28.90% REBIT/Sales and services 10.40% 10.90% Net profit 24 294 61 189 36 895 151.90% (1) CAGR: compound annual growth rate (2) REBITDA: recurring earnings before interest, taxes, depreciation, and amortization.
    [Show full text]
  • Clinical Policy: Proton and Neutron Beam Therapies Reference Number: CP.MP.70 Coding Implications Last Review Date: 11/20 Revision Log
    Clinical Policy: Proton and Neutron Beam Therapies Reference Number: CP.MP.70 Coding Implications Last Review Date: 11/20 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Proton beam therapy (PBT) is a form of external beam radiation therapy (EBRT) that utilizes protons (positively charged subatomic particles) to precisely target a specific tissue mass. Proton beams can penetrate deep into tissues to reach tumors, while delivering less radiation to surrounding tissues. This may make PBT more effective for inoperable tumors, or for those areas in which damage to healthy tissue would pose an unacceptable risk. Neutron beam therapy (NBT) is a less widely available form of EBRT that utilizes neutrons. Its clinical use is very limited due to difficulties in the delivery of this treatment modality. Policy/Criteria I. It is the policy of health plans affiliated with Centene Corporation® that proton beam therapy is medically necessary for the following indications: A. Ocular tumors with no distant metastasis. Fiducial markers (tantalum clips) are permitted to allow eye and tumor position verification; or B. Primary or metastatic tumors of the spine where the spinal cord tolerance may be exceeded with conventional treatment or where the spinal cord has previously been irradiated; or C. Tumors that approach or are located at the base of the skull, including but not limited to: chordoma or chondrosarcoma; or D. Primary hepatocellular cancer treated in a hypofractionated regimen; or E. Primary or benign solid tumors in members/enrollees ≤ 18 years old; or F. Genetic syndromes making total volume of radiation minimization crucial such as but not limited to NF-1 patients and retinoblastoma; or G.
    [Show full text]
  • Clinical Progress in Proton Radiotherapy: Biological Unknowns
    cancers Review Clinical Progress in Proton Radiotherapy: Biological Unknowns Laura Vanderwaeren 1,2,3 , Rüveyda Dok 1, Kevin Verstrepen 2,3 and Sandra Nuyts 1,4,* 1 Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, 3000 Leuven, Belgium; laura.vanderwaeren@kuleuven.be (L.V.); ruveyda.dok@kuleuven.be (R.D.) 2 Laboratory of Genetics and Genomics, Centre for Microbial and Plant Genetics, KU Leuven, 3000 Leuven, Belgium; kevin.verstrepen@kuleuven.be 3 Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3000 Leuven, Belgium 4 Department of Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 Leuven, Belgium * Correspondence: sandra.nuyts@uzleuven.be; Tel.: +32-1634-7600; Fax: +32-1634-7623 Simple Summary: Proton radiation therapy is a more recent type of radiotherapy that uses proton beams instead of classical photon or X-rays beams. The clinical benefit of proton therapy is that it allows to treat tumors more precisely. As a result, proton radiotherapy induces less toxicity to healthy tissue near the tumor site. Despite the experience in the clinical use of protons, the response of cells to proton radiation, the radiobiology, is less understood. In this review, we describe the current knowledge about proton radiobiology. Abstract: Clinical use of proton radiation has massively increased over the past years. The main reason for this is the beneficial depth-dose distribution of protons that allows to reduce toxicity to normal tissues surrounding the tumor. Despite the experience in the clinical use of protons, the radiobiology after proton irradiation compared to photon irradiation remains to be completely elucidated. Proton radiation may lead to differential damages and activation of biological processes.
    [Show full text]
  • BCBS AL Radiation Therapy Guidelines V3.0.2019
    CLINICAL GUIDELINES Radiation Therapy V3.0.2019 Effective July 15, 2019 Clinical guidelines for medical necessity review of radiation therapy services. © 2019 eviCore healthcare. All rights reserved. Radiation Therapy Criteria V3.0.2019 Please note the following: CPT Copyright 2017 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. ______________________________________________________________________________________________________ © 2019 eviCore healthcare. All Rights Reserved. Page 2 of 251 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Radiation Therapy Criteria V3.0.2019 Please note the following: All information provided by the NCCN is “Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™)©2018/2019 National Comprehensive Cancer Network. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.” ______________________________________________________________________________________________________ © 2019 eviCore healthcare. All Rights Reserved. Page 3 of 251 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Radiation Therapy Criteria V3.0.2019 Dear Provider, This document provides detailed descriptions of eviCore’s basic criteria (also known as clinical guidelines) for radiation therapy arranged by diagnosis. They have been carefully researched and are continually updated in order to be consistent with the most current evidence-based guidelines and recommendations for the provision of radiation therapy from national medical societies and evidence-based medicine research centers. In addition, the criteria are supplemented by information published in peer-reviewed literature.
    [Show full text]
  • Models for Translational Proton Radiobiology—From Bench to Bedside and Back
    cancers Review Models for Translational Proton Radiobiology—From Bench to Bedside and Back Theresa Suckert 1,2 , Sindi Nexhipi 1,3 , Antje Dietrich 1,2 , Robin Koch 4,5,6 , Leoni A. Kunz-Schughart 1,7 , Emanuel Bahn 4,5,6,8 and Elke Beyreuther 1,9,* 1 OncoRay—National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, 01309 Dresden, Germany; theresa.suckert@uniklinikum-dresden.de (T.S.); sindi.nexhipi@uniklinikum-dresden.de (S.N.); Antje.Dietrich@uniklinikum-dresden.de (A.D.); leoni.kunz-schughart@oncoray.de (L.A.K.-S.) 2 German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany 3 Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, 01309 Dresden, Germany 4 Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany; robin.koch@dkfz-heidelberg.de (R.K.); e.bahn@dkfz-heidelberg.de (E.B.) 5 Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany 6 National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany 7 National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany 8 German Cancer Research Center (DKFZ), Clinical Cooperation Unit Radiation Oncology, 69120 Heidelberg, Germany 9 Helmholtz-Zentrum Dresden—Rossendorf, Institute of Radiation Physics, 01328 Dresden, Germany * Correspondence: elke.beyreuther@uniklinikum-dresden.de Citation: Suckert, T.; Nexhipi, S.; Dietrich, A.; Koch, R.; Simple Summary: An increasing number of cancer patients are treated with proton therapy. Never- Kunz-Schughart, L.A.; Bahn, E.; theless, there are still open questions that require preclinical studies, for example, those regarding Beyreuther, E.
    [Show full text]
  • Proton Beam Radiation Therapy – Commercial Medical Policy
    UnitedHealthcare® Commercial Medical Policy Proton Beam Radiation Therapy Policy Number: 2021T0132CC Effective Date: May 1, 2021 Instructions for Use Table of Contents Page Related Commercial Policy Coverage Rationale ........................................................................... 1 • Intensity-Modulated Radiation Therapy Documentation Requirements......................................................... 2 • Radiation Therapy: Fractionation, Image-Guidance, Definitions ........................................................................................... 2 and Special Services Applicable Codes .............................................................................. 2 • Stereotactic Body Radiation Therapy and Description of Services ..................................................................... 4 Stereotactic Radiosurgery Clinical Evidence ............................................................................... 4 U.S. Food and Drug Administration ..............................................18 Community Plan Policy References .......................................................................................18 • Proton Beam Radiation Therapy Policy History/Revision Information..............................................23 Medicare Advantage Coverage Summary Instructions for Use .........................................................................23 • Radiologic Therapeutic Procedures Coverage Rationale Note: This policy applies to persons 19 years of age and older. Proton beam radiation
    [Show full text]
  • Best Practices in Identifying Proton-Appropriate Patients Presented by Dr
    Best Practices in Identifying Proton-Appropriate Patients Presented by Dr. Ramesh Rengan Professor, Department of Radiation Oncology, University of Washington School of Medicine Medical Director, SCCA Proton Therapy Center Radiation Oncologist, University of Washington Medical Center Introduction Protons are a form of radiation treatment that, for a subset of patients, may provide a clinical benefit when compared with standard radiotherapy. 2 Finding the 3% Your challenge: Proton therapy is appropriate in only How can I make sure that 3-10% of solid tumor cases. my patient is But for that group, getting the best there are many expected treatment plan? clinical benefits. 3 Clinical Benefits of Proton Therapy • Ability to apply higher therapeutic dosages, because the beam delivers the most radiation at the tumor site, reducing overall exposure • Expected reduction in radiation-caused secondary cancers - Particularly critical to young people and pediatric cases - Important to anyone with long life expectancy • Less radiation damage to nearby healthy tissue - Particularly important in ocular, brain, lung and breast cancers • Clinical evidence to support fewer side effects compared to X-rays in certain patients So Why Only 3-10%? • 30% of solid tumor cancer patients receive radiation (of any type) Cases suitable for proton therapy • Protons are not generally applicable for metastasized cancers – Half of the 60% are treated for palliative, versus curative, care Of 100% of cancer cases … • Limited resource 60% of these are solid tumor cases 30% of these are suitable for radiation • Cost 3-10% of these are suitable for protons • Complexity of treatment planning and delivery • Availability of proton centers 5 When Is Proton Therapy Appropriate? Will share infographic section once final.
    [Show full text]
  • Intensity Modulated Proton Therapy Backgrounder
    MD Anderson Cancer Center offers next evolution of cancer treatment with intensity modulated proton therapy New technological capabilities further refine radiation therapy options for complicated head and neck tumors Selected for its ability to target tumors precisely while minimizing damage to healthy surrounding tissue, proton therapy has rapidly gained a foothold as an option for radiation treatment in the past decade. The Proton Therapy Center at The University of Texas MD Anderson Cancer Center in Houston, Texas, continues to innovate the field by being the first and only center in North America to treat patients with the most advanced form of proton therapy, called intensity modulated proton therapy with multi-field optimization (IMPT). Opened in 2006 as the first proton therapy center at a major comprehensive cancer center, it is now one of 10 proton therapy centers currently operating in the United States. The Proton Therapy Center treats over 800 patients of all ages every year. IMPT, considered the “holy grail” by many radiation oncologists, is best used to deliver a potent and precise dose of protons to the most complicated tumors, ones that largely reside embedded in the nooks and crannies of the head and neck or skull base. MD Anderson envisioned IMPT as an achievable reality when the Proton Therapy Center introduced pencil beam technology in 2008 for patients with cancers of the pelvis, brain and certain pediatric tumors. Like pencil beam, IMPT relies on complex treatment planning systems and an intricate network of magnets to focus and aim a narrow proton beam and essentially “paint” the radiation dose onto the tumor layer by layer.
    [Show full text]